F2G
F2G is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections. F2G has discovered and developed a completely new class of antifungal agents called the orotomides. F2G is based in the U.K., the U.S. and Austria.
Sector
Biopharmaceuticals
Strategy
Crossover
Status
Live
Website
www.f2g.com
Related News
F2G receives complete response letter from FDA for New Drug Application for Olorofim for the treatment of invasive fungal infections; plans resubmission with additional data and analyses
F2G moves UK headquarters to MediaCity
F2G announces FDA filing acceptance of New Drug Application for olorofim for the treatment of invasive fungal Infections
F2G announces data from Phase 2b study at ID Week 2022 showing positive therapeutic response in patients with invasive fungal infections treated with Olorofim
F2G announces $70 million financing to advance development and commercialization of new antifungal agent olorofim
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.